Utilizing AI to Streamline Clinical Development

Dr. Jeff Humphrey has a record of performance at BMS, Pfizer, Bayer, Kyowa Kirin, Constellation, and other Boston-based biotechnology companies that highlights his expertise in drug development, team building, and organizational leadership. He has led high-performance teams to US and European regulatory approvals of oncology, neurology, and rare disease therapies (Nexavar, Poteligeo, Nourianz, and Crysvita), indicating his deep understanding of scientific research and regulatory processes. His leadership roles as CMO and CDO at various innovative companies demonstrate his ability to develop and guide teams through complex challenges in the drug development cycle.Dr. Humphrey's academic background at Harvard, Johns Hopkins, and the National Cancer Institute, along with his extensive publication record (https://scholar.google.com/citations?user=qk1zVkAAAAAJ&hl=en), underscores his commitment to advancing medical science to help people struggling with serious illness.

Mohammed Asmal, MD, PhD, has a long-standing interest in gene and cell therapy and is Chief Medical Officer at Prime Medicine. He is a physician-scientist with an AB in biology and biomedical engineering from Harvard University, and an MD-PhD in molecular and cellular biology from Columbia University. He trained in internal medicine and infectious diseases at the Brigham and Women’s and Massachusetts General Hospitals, and has devoted much of his academic career to studying the virology and immunology of HIV, and to treating patients with HIV and other infectious diseases in the clinic. After leaving academic medicine, Dr. Asmal took on roles in clinical development at Vertex Pharmaceuticals, where he led trials in oncology and hepatitis C, bringing multiple small molecules into the clinic through phase II. He subsequently transitioned to bluebird bio, where he led the clinical development team, overseeing lentiviral-based gene therapy programs in rare disease and oncology, culminating in the first approval of a gene therapy for a hemoglobinopathy in the world. Immediately prior to joining Prime Medicine, Dr. Asmal was a venture partner at OrbiMed Advisors, LLC, where he performed diligence on potential investments in the cell and gene therapy, COVID-19 and oncology spaces, and oversaw a seed stage investment in cell therapy.

Scott Chetham Ph.D. is an experienced healthcare entrepreneur who is currently the CEO and co-founder of Faro Health. Scott leads the strategy for the Faro Health platform, which is designed to power clinical development by connecting data to decision making in a fundamentally new way. Previously, he was the Head of Clinical Research Operations and Data Management at Verily Life Sciences, formerly known as Google Life Sciences. This multi-faceted strategic and operational role involved leading the clinical strategy, clinical teams, process development and operations for all clinical projects of the company, including Google and Google[x]. Scott has also served as a Venture Partner at Versant Ventures, CTO and Co-founder of Intersection Medical (sold to ImpediMed), and VP Clinical Affairs (ImpediMed). In these latter two roles he was responsible for clinical research strategy and operations.

Dr Gen Li is the President and Founder of Phesi Inc., the clinical data science company that helps the biopharmaceutical industry deliver smarter trials and faster cures. Dr Li has extensive experience in clinical development, having previously worked at Bristol-Myers Squibb, Pfizer and Pharmacia, where he significantly contributed to the Centre for Medicines Research (CMR) International database for pharmaceutical R&D performance. He was the first to drive the implementation of Balanced Scorecard in a top clinical development organization. His work inspired him to create Phesi - ensuring the insights held from historical data, or data collected from failed clinical trials were not lost. Under Dr Li’s leadership, Phesi has supported a number of landmark trials including Keytruda with its integrated solutions that accelerate drug development and commercialization. Phesi continues to disrupt the industry with its AI-driven Trial Accelerator™ platform that harnesses the industry’s largest database of global real-world patient data to generate Digital Patient Profiles, Digital Twins and External Control Arms. Phesi delivers actionable insights for trial design, planning and execution, enabling pharma and biopharma companies to optimize protocol design, improve enrollment and reduce patient and investigator site burden and cycle times.

Peter Linde, MD, FASN, is a clinical development leader with 19 years of experience in leading global teams for Phase I and II clinical trials at companies like Morphic Therapeutics, Acceleron, and Abbvie. In his role at Thermo Fisher Scientific, he supports biotech customers as vice president, global medical officer for the PPD clinical research business. His work has resulted in four global regulatory approvals and company acquisitions by Merck and Lilly. He holds two U.S. patents in stem cell biology and extracorporeal organ devices, with another pending for Sotatercept in Pulmonary Arterial Hypertension. Peter completed nephrology and transplant fellowships at Massachusetts General Hospital/Harvard and served as a Clinical Assistant Professor of Medicine at UCSF prior to his career in the pharmaceutical industry.